South Korea
· Delayed Price · Currency is KRW EyeGene Company Description
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea.
The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer.
It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster.
In addition, the company provides vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 47 |
| CEO | Won-Il Yoo |
Contact Details
Address: B-1211, 401 Yangcheon-ro Seoul, 07528 South Korea | |
| Phone | 82 2 322 1687 |
| Website | eyegene.co.kr |
Stock Details
| Ticker Symbol | 185490 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Won-Il Yoo | Chief Executive Officer |
| Soobeom Lee | Chief Financial Officer |